The anti-CD133 antibody-conjugated SN-38-loaded nanoparticles named CD133Ab-NPs-SN-38 has been designed to target CD133+ cells in colorectal cancer, and the results indicated that it could eliminate and suppress cancer growth and recurrence in an HCT116 xenograft model (134). The gene discussed is PROM1; the disease is cancer.